Search PubMed⌕ Search

Biomedical subjects

K Hole

Publications and source records attributed to K Hole.

At least 73 records · Page 4Linked to original sources

Both single-dose and repeated administration of clomipramine reduces the behavioural response to intrathecal capsaicin in mice.

Capsaicin injected intrathecally releases substance P from primary sensory nerve endings, and induces a pain related behaviour in mice consisting of licking, biting and scratching directed to the distal part of the body. This behavioural response was reduced by approximately 35% after intraperitoneal administration of clomipramine, 10 mg/kg, 1 hr in advance, and by 38% after repeated administration (10 mg/kg/day for 9 days). Twenty-four hr after the last repeated clomipramine injection, the response after capsaicin was still reduced by 36%, indicating a long-lasting effect of repeated treatment. The results indicate that clomipramine has analgesic properties against pain of central origin both after single-dose and repeated administration.

Animals↗

Intrathecal substance P modulates the depressant effect of 5-methoxy-N,N-dimethyltryptamine on a reflex response to radiant heat in mice.

The effect of intrathecal (i.th.) substance P (SP) on antinociception elicited by the serotonin (5-HT) receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) was investigated in mice by means of the tail-flick method. Substance P (0.07, 0.7 or 7 micrograms) induced a behavioral syndrome for 1-2 min, but had no apparent toxic or neurologic effects and did not alter the tail-flick response to noxious radiant heat 30 min after injection. The depressant effect of 5-MeODMT (3 mg/kg) on tail-flick responses was, however, markedly attenuated when administered 30 min after SP. The tail skin temperatures of vehicle- and SP-injected mice were nearly identical 30 min after i.th. injection as well as after administration of 5-MeODMT. The results indicate a functional interaction between SP and 5-HT in spinal nociceptive processes, and it is suggested that i.th. SP modulates the function of 5-HT receptors.

Animals↗

Response latencies in the tail-flick test depend on tail skin temperature.

Tail skin temperatures and tail-flick latencies were simultaneously recorded in male Sprague-Dawley rats exposed to various ambient temperatures (22-30 degrees C). There was a positive correlation between tail skin temperature and ambient temperature and a negative correlation between tail-flick latency and ambient temperature. Importantly, a highly significant negative correlation was present between tail-flick latency and skin temperature, even at constant ambient temperature (22.1 or 23.3 degrees C). Thus, the results of tail-flick testing are highly affected by skin temperature and factors altering the skin temperature must be considered when tail-flick latencies are interpreted in terms of nociception.

Animals↗

5-HT depletion with 5,7-DHT, PCA and PCPA in mice: differential effects on the sensitivity to 5-MeODMT, 8-OH-DPAT and 5-HTP as measured by two nociceptive tests.

Depletion of 5-hydroxytryptamine (5-HT) in mice was produced by intracerebroventricular injection of 5,7-dihydroxytryptamine (5,7-DHT, 80 micrograms) or by systemic injections of p-chloroamphetamine (PCA, 3 X 40 or 4 X 40 mg/kg), p-chlorophenylalanine (PCPA, 5 X 400 or 14 X 400 mg/kg) or combined PCA (3 X 40 mg/kg) + PCPA (11 X 400 mg/kg). Neither of the pretreatments altered nociception in the increasing temperature hot-plate test, whereas hyperalgesia was demonstrated in 5,7-DHT lesioned animals in the tail-flick test. 5,7-DHT-pretreatment enhanced the antinociceptive effect of the 5-HT agonists 5-methoxy-N,N-dimethyltryptamine (5-MeODMT), 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 5-hydroxytryptophan (5-HTP). This effect was observed after 2, 5 and 8 days in the tail-flick test and after 5 and 8 days in the hot-plate test. However, pretreatment with PCPA or PCA failed to alter the antinociception elicited by the 5-HT agonists, although a tendency towards enhancement of antinociception was found after combined treatment with PCA and PCPA. It is suggested that the injection of 5,7-DHT induces denervation supersensitivity of post-synaptic 5-HT receptors. The lack of such supersensitivity after PCPA-pretreatment which induces similar 5-HT depletion to 5,7-DHT, may suggest that other factors than the absence of 5-HT may contribute to the development of denervation supersensitivity. Alternatively, the three 5-HT depleting agents may produce a qualitatively different reduction of 5-HT.

5,7-Dihydroxytryptamine↗

Mechanisms by which the putative serotonin receptor antagonist metitepin alters nociception in mice.

The putative serotonin (5-HT) receptor antagonist metitepin (0.5 mg/kg, intraperitoneally) produced hypoalgesia in the increasing temperature hot-plate test and hyperalgesia in the tail-flick test in mice. The effects of metitepin were not altered after depletion of 5-HT by the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT, 80 micrograms free base, intracerebroventricularly) or the serotonin synthesis inhibitor p-chlorophenylalanine (PCPA, 400 mg/kg for 10 consecutive days). After chronic administration (2 or 5 mg/kg for 18 consecutive days) tolerance to the effect of metitepin (0.5 mg/kg) and cross-tolerance to the antinociceptive effect of the 5-HT agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg) was found in the hot-plate test but not in the tail-flick test. It is suggested that metitepin may block descending 5-HT transmission while more complex mechanisms of action are involved at supraspinal level. One possibility is that metitepin exhibits partial agonist properties or, alternatively, that the drug may block 5-HT subsystems which tonically enhance nociception.

5,7-Dihydroxytryptamine↗

Increased behavioural response to intrathecal substance P after intracerebroventricular 5,7-dihydroxytryptamine but not after p-chlorophenylalanine administration.

The behavioural response to intrathecally injected substance P (SP, 1.25 ng) was investigated in mice after lesioning of serotonergic (5-HT) pathways by intracerebroventricular 5,7-dihydroxytryptamine (5,7-DHT, 80 micrograms base/mouse) and after 5-HT synthesis inhibition by p-chlorophenylalanine (PCPA, 400 mg kg-1 for 6 consecutive days). Pretreatment with 5,7-DHT and PCPA reduced the 5-HT level in the spinal cord to 6 and 7% of controls and the noradenaline (NA) level to 69 and 84% of controls, respectively. Intrathecally injected SP produced a response consisting of vigorous biting, licking and scratching of the caudal part of the body. The response to SP was significantly increased 5 days after injection of 5,7-DHT, but only a non-significant tendency towards enhancement of the response was found after 24 h. There was no change in the response to SP 24 h after the last injection of PCPA. It is suggested that 5,7-DHT but not PCPA induces receptor supersensitivity to SP, and that reduction in spinal SP by 5,7-DHT may be a factor in this change in receptor sensitivity.

5,7-Dihydroxytryptamine↗

Increased behavioural response to intrathecal serotonin after lesion of serotonergic pathways with 5,7-dihydroxytryptamine seems not to be due to depletion of serotonin.

The behavioural response to intrathecal i.th. serotonin (5-HT) was examined in mice pretreated with the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) or the 5-HT synthesis inhibitor p-chlorophenylalanine (PCPA) which produce similar extensive depletion of central 5-HT levels. Intrathecal 5-HT (0.4 micrograms) elicited a behavioural response consisting of reciprocal hindlimb scratching and biting or licking of the hindquarters indicative of nociceptive stimulation. The response to i.th. 5-HT was markedly increased 5 days after intracerebroventricular (i.c.v.) injection of 5,7-DHT (80 micrograms base per mouse). On the other hand, 24 h after the last pretreatment injection of PCPA (400 mg kg-1 for 6 consecutive days), the response to i.th. 5-HT was unaltered. These results indicate that i.c.v. 5,7-DHT produces supersensitivity to 5-HT. Since PCPA failed to alter the effect of 5-HT, the supersensitivity seems not to be due to depletion of 5-HT levels after the lesion.

5,7-Dihydroxytryptamine↗

Apparent hyperalgesia in the mouse tail-flick test due to increased tail skin temperature after lesioning of serotonergic pathways.

The relationship between tail skin temperature and responsiveness to noxious radiant heat in the tail-flick test was investigated in mice. A significant negative correlation between tail skin temperature and tail-flick latency was found when the tail skin temperature was increased by elevating the ambient temperature. After intracerebroventricular injection of the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT, 80 micrograms) tail skin temperatures were increased and tail-flick latencies reduced. In contrast, administration of the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA, 400 mg kg-1 for 5 consecutive days) lead to a slight lowering of tail temperatures and a tendency towards elevation of tail-flick latencies. The results show that factors which affect tail skin temperature also influence the tail-flick test in mice. The divergent effects of 5,7-DHT and PCPA on tail-flick responsiveness may be due to the different effects of these compounds on the tail skin temperature. The results suggest that the reduced tail-flick latency after partial destruction of serotonergic pathways by 5,7-DHT is due primarily to the increased tail skin temperature. The dependence of tail-flick latency on tail skin temperature limits the usefulness of the tail-flick test unless changes in tail skin temperature are controlled for.

5,7-Dihydroxytryptamine↗

Attention deficit disorders: a study of peptide-containing urinary complexes.

In several behavioral disorders, we have observed that abnormal amounts of peptides and protein-associated peptide complexes are excreted in the urine. The gel filtration patterns of these excreted substances have some specificity for the different disorders. The urinary excretion of peptide-containing complexes was studied in 91 boys and 13 girls (mean age 9.4 years, range 1-23) with the clinical diagnosis of attention deficit disorder (ADD), with or without hyperactivity. The gel filtration of urine precipitate showed patterns in all patients that were different from those seen in 36 normal controls. Sixty-four patients had increased benzoic acid-glycoprotein-peptide complexes in the late peaks. The symptoms of all these patients fit the criteria for diagnosis of attention deficit disorder with hyperactivity (ADDH). Thirty-five patients showed reduced amounts of uric acid complexes in the late peaks. Clinically, this group, with the exception of three patients, fit the criteria for diagnosis of attention deficit disorder without hyperactivity. Five patients showed reduced amounts of all urinary complexes; four of these were hyperactive. Moderate exercise in control children did not change the urinary pattern. One urinary peptide fraction from hyperactive patients, purified to homogeneity, increased the uptake of 14C[5-HT] in platelets. Strict clinical, neuropsychological, and psychophysiological selection of the patients reduced the heterogeneity of the patterns. Although more studies are needed, the findings seem promising for the possibility of developing biochemical tests that may be helpful diagnostically.

Adolescent↗

Involvement of central serotonergic pathways in nefopam-induced antinociception.

The possible involvement of central serotonergic pathways in the mechanism of action of nefopam was investigated in male albino mice. Nefopam (15 mg/kg i.p.) did not alter the concentration of serotonin or its metabolite 5-hydroxyindole acetic acid in frontal cortex or spinal cord. Lesions of the ascending serotonergic pathways were made by systemic administration of p-chloroamphetamine (PCA). Serotonin depletion in all serotonergic systems was obtained by means of p-chlorophenylalanine (PCPA). Two different nociceptive assays were used, the formalin test and the increasing temperature hot plate test. PCPA pretreatment significantly reduced the effect of nefopam (15 mg/kg) in the formalin test. In contrast, nefopam-induced analgesia was not affected by PCA pretreatment, either in the formalin test or in the increasing temperature hot plate test. In conclusion, the data suggest that descending serotonergic pathways are involved in nefopam-induced antinociception.

Analgesics↗

Increased sensitivity to intrathecal substance P following chronic administration of zimelidine.

The behavioural response to intrathecal substance P (SP) was evaluated following acute and chronic administration of the selective serotonin reuptake inhibitor zimelidine. A single dose of zimelidine (10 mg/kg) attenuated the response to SP by approximately 40%, in agreement with previous findings that acute administration of zimelidine reduces nociceptive behaviour. Twenty-four hours following the withdrawal of long-term treatment with zimelidine (10 mg/kg X 2 daily for 14 days) the behavioural response to SP was increased by 116%. This may indicate the development of supersensitivity to SP, or may reflect an increased responsiveness to noxious stimuli due to reduced serotonergic inhibition.

Animals↗

Development of tolerance to the antinociceptive effect of metergoline.

Metergoline given IP reduced the response to noxious stimulation in the mouse formalin test. Tolerance to this effect developed after a chronic treatment schedule consisting of ten daily injections of 5 mg/kg. Twenty four hours after the last injection a test dose of metergoline (2.5 mg/kg) reduced the licking time in the formalin test by 28% in the chronic metergoline group, compared to 68% reduction in the vehicle-treated animals. In addition, the antinociceptive effect of the 5-hydroxytryptamine releasing compound p-chloramphetamine (PCA) was reduced following chronic treatment with metergoline. The reduced effect of PCA may have been caused by down-regulation of 5-HT2 receptors. However, this finding is also compatible with the contention that metergoline may act as an agonist at postsynaptic serotonergic receptors.

Animals↗

Changes in nociception after acute and chronic administration of zimelidine: different effects in the formalin test and the substance P behavioural assay.

The selective inhibitor of the reuptake of 5-hydroxytryptamine (5-HT), zimelidine, was administered intraperitoneally to mice (10 mg/kg) and nociceptive sensitivity was evaluated using the formalin test (20 microliters of 1% formalin, injected subcutaneously) and the assay for substance P (5 ng administered intrathecally). Zimelidine increased the behavioural response to formalin, but reduced the response to substance P. These effects of zimelidine seemed to be unchanged after chronic treatment (2 X 10 mg/kg for 14 days). It is suggested that zimelidine produces a central antinociceptive effect, but elicits a peripheral hyperalgesia, which predominates in the formalin test.

Animals↗

The effect of diazepam on nociception in mice.

The antinociceptive properties of diazepam were evaluated in mice, using four different pain tests and different doses of the drug (0.2, 0.5, 1.0 and 2.0 mg/kg). In the tail flick test and the increasing temperature hot plate test there were no effects. In the formalin test reduced licking was observed for the highest dose of diazepam. However, this dose also induced clear sedation possibly causing the reduced licking response. In the constant temperature hot plate test a hyperalgesia was found for all doses tested. This hyperalgesia was not observed in animals adapted to the test apparatus, suggesting that the "hyperalgesic" effect of diazepam may be due to reduced stress analgesia. The serum concentrations of the drug were comparable to therapeutic levels in humans. It was concluded that the sedative and anxiolytic effects of diazepam may influence the results of nociceptive tests, but the drug has probably no effect on nociception in itself.

Analgesics↗

Antinociceptive effects of (+/-)-, (+)- and (-)-nefopam in mice.

The antinociceptive activity of (+/-)-, (+)- and (-)-nefopam in mice has been examined using the hot-plate, formalin and tail-flick tests. Nefopam was administered by the intraperitoneal, intracerebroventricular (i.c.v.) and intrathecal (i.th.) routes. Intraperitoneal injection of (+/-)-nefopam (10-20 mg kg-1) had powerful analgesic effects in the hot-plate and formalin tests. In the tail-flick test it produced a weak, but significant elevation of the response latencies. In spinalized animals, however, the effect was abolished, indicating that nefopam prolonged the tail-flick latencies by activation of descending pain-modulating pathways. (+/-)-Nefopam (5-20 micrograms) elicited analgesia in the hot-plate test after i.c.v. or i.th. injection. These findings suggest that nefopam has both a spinal and a supraspinal site of action. (+)-Nefopam was significantly more potent than (-)-nefopam after both systemic and central administration.

Analysis of Variance↗

Evidence from behavioural and in vitro receptor binding studies that the enkephalinergic system does not mediate acute ethanol effects.

The behavioural disturbances produced by acute exposure to ethanol have been related to changes in function of the opioid systems in the CNS. However, evidence in the literature is conflicting. The present report concerns the possible role of the enkephalinergic system in the mediation of acute ethanol effects. We used rats to study the ability of a selective opioid delta receptor antagonist (ICI 154129) to prevent the effect of ethanol on pain sensitivity, body temperature, sensorimotor performance and level of consciousness. Furthermore, in vitro receptor binding was measured to investigate whether or not ethanol, within a non-lethal concentration range, would change the binding parameters of the delta receptor ligand [3H][D-ala2, D-Leu5]enkephalin. ICI 154129 did not significantly influence the effects of ethanol in the behavioural experiments. Ethanol did not significantly change the binding parameters whether saturation or competition was measured in the receptor binding experiments. Thus, there was no evidence that the enkephalinergic system mediated the acute ethanol effects.

Animals↗

Changes in nociception after 6-hydroxydopamine lesions of descending catecholaminergic pathways in mice.

Intrathecal (ITH) administration of 5 micrograms 6-hydroxydopamine (6-OHDA) in mice selectively lesioned descending catecholaminergic pathways. Uptake of 3H-noradrenaline (3H-NA) into synaptosomes from the lumbar spinal cord was reduced by 95%, without any change in the uptake of 14C-5-hydroxytryptamine (14C-5-HT). Synaptosomal uptake of 3H-NA and 14C-5-HT in the brain was not altered. The nociceptive sensitivity was evaluated using the tail-flick, hot plate and formalin tests 3 and 14 days after injection of 6-OHDA. At day 3 hyperalgesia was found in the hot-plate test, unchanged response latency in the tail-flick test and hypoalgesia in the formalin test. At day 14 there were no statistically significant differences from controls in any of the tests. The present findings support the contention that catecholaminergic pathways participate in the tonic regulation of nociception in the spinal cord. However, while supraspinally integrated responses to acute thermal pain, as measured with the hot-plate test, are inhibited by these pathways, responses to prolonged chemical pain are enhanced.

Animals↗

Effects of the putative 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)tetralin on nociceptive sensitivity in mice.

The ability of 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT) to alter nociceptive sensitivity in mice was studied using the tail-flick, hot-plate and formalin tests. Subcutaneous (SC) administration of 8-OH-DPAT (0.63-1.0 mg/kg) dose-dependently increased the temperature at which hindpaw lick occurred in a hot-plate test using slowly rising temperature and increased the latencies to hindpaw lick, but reduced the latencies to jump in a conventional hot-plate test. Intracerebroventricular (ICV) injections (0.25-1.0 microgram) produced similar results in the conventional hot plate test. Following intrathecal (ITH) injections (0.25-1.0 microgram), however, the latencies to hindpaw lick were elevated without any change in jump latencies. In the formalin test a low systemic dose of 8-OH-DPAT (0.063 mg/kg) elicited hyperalgesia, while hypoalgesia was found after a high dose (1.0 mg/kg). ICV injection of 1.0 microgram produced hypoalgesia in the formalin test while the same dose injected ITH was without effect. 8-OH-DPAT did not alter tail-flick latencies, either by SC, ICV or ITH administration. Previous studies have shown that 8-OH-DPAT stimulates central serotonergic receptors, and shows selectivity for the 5-HT1A recognition site. The present findings indicate an involvement of 5-HT1A receptors in the processing of nociceptive information both at spinal and supraspinal sites. However, stimulation of 5-HT1A receptors does not seem to affect spinal, nociceptive reflexes.

8-Hydroxy-2-(di-n-propylamino)tetralin↗